Nexium Could See Formulary Benefit From Prilosec OTC, AstraZeneca Says
Executive Summary
AstraZeneca Nexium sales could benefit from Prilosec OTC's effect on formulary coverage for proton pump inhibitors, CFO Jonathan Symonds said during an Oct. 23 quarterly earnings call
You may also be interested in...
Big Pharma’s “Black Wednesday”: Quarterly Reports Underscore Uncertainty
An unprecedented string of poor third-quarter earnings reports from the top pharmaceutical companies illustrates the importance of the Medicare debate to the future of the drug industry
Big Pharma’s “Black Wednesday”: Quarterly Reports Underscore Uncertainty
An unprecedented string of poor third-quarter earnings reports from the top pharmaceutical companies illustrates the importance of the Medicare debate to the future of the drug industry
PPI Coverage Adjusts To Prilosec OTC; Wyeth Sees Growth For Protonix In ‘04
Wyeth expects Protonix (pantoprazole) to remain a readily available "tier 2" agent in most health plans during 2004 despite the changing dynamics in the proton pump inhibitor market